RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

 

Regulatory Focus™ > News Articles > Indian Regulators Call for Comment on Revised Clinical Trial Standards

Indian Regulators Call for Comment on Revised Clinical Trial Standards

Posted 01 December 2014 | By Louise Zornoza

Indian Regulators Call for Comment on Revised Clinical Trial Standards

This content is provided by RegLink News, publishers of e-weekly global regulatory news. RegLink offers a 30-day free trial and 15% discount on Global Update subscriptions to RAPS members.

India’s Central Drugs Standard Control Organization (CDSCO), the country's medicines regulator, is seeking input from the public on draft revised accreditation standards for clinical trials.

The standards were prepared by the National Accreditation Board for Hospitals and Healthcare Providers (NABH) and the Quality Council of India, in consultation with various stakeholders.

The draft sets out the criteria for the accreditation of ethics committees, investigators and the sites where clinical trials are to be carried out.

The deadline for comments is December 15, 2014.


Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe

Regulatory Focus™ is doing essential, non-biased journalism during this unprecedented time. We appreciate your support as we bring you the news and intelligence you need to make an impact on global healthcare.

Regulatory Focus™ provides the intelligence you need to impact global healthcare during this crisis. Thank you for your support.